Liothyronine sodium - Thyrotoxicosis
You are here : Home > Formulary Search > Liothyronine sodium - Thyrotoxicosis
Status 1
- Capsules
Status 2
- Oral solution
The oral solution has not been reviewed for addition to the formulary. Please contact your Pharmacy Team for advice.
This formulation has not yet been assessed for formulary status and is not currently on the APC work-plan.
It has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.
Before prescribing, it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.
The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net if they wish to make a submission.
Documentation
PAD Profile
Other Indications
Below are listed other indications that Liothyronine sodium is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Thyrotoxicosis.
- No records returned.
Committee Recommendations (1)
In March 2016 the APC (formerly PCN) agreed liothyronine (T3) as an option in the management of hypothyroid states occuring in the treatment of thyrotoxicosis and assigned it a RED traffic light status for this indication.
Licensed, bioequivalent liothyronine CAPSULES have entered the market at a considerably reduced price and the APC recommend that:
- the most cost effective preparation should be prescribed (currently capsules) in all new patients
- prescribers should consider switching existing patients from tablets to capsules - for discussion with the patient at next review
The APC noted the additional information provided in the Liothyronine capsules - briefing paper below